本文评价新型钙抗剂伊拉地平静滴时的血液动力学作用、耐受性,以及与血浆浓度的关系。 10例充血性心力衰竭患者,心功能级别为Ⅱ～Ⅳ级。进入本研究至少1周前,停用所有血管扩张剂、β阻滞剂、钙拮抗剂。测定血液动力学指标。继之,测定心率、平均血压、平均动脉压、右心房压、肺动脉压、平均肺毛细血管楔压、心输出量、动静脉混合氧差。静滴伊拉地平前、中、后记录心电图。试验分两步用药,第一步,30分钟内静滴本品每分钟0.1μg/kg第二步,30分钟内静滴本 This article evaluates the hemodynamic effects, tolerability, and plasma concentration of a novel calcium antagonist, intrarapidilazapine. Ten patients with congestive heart failure, cardiac function grade Ⅱ ~ Ⅳ level. All vasodilators, beta blockers, and calcium antagonists were discontinued at least 1 week prior to entering the study. Determination of hemodynamic parameters. Subsequently, heart rate, mean blood pressure, mean arterial pressure, right atrial pressure, pulmonary arterial pressure, mean pulmonary capillary wedge pressure, cardiac output, arterial and venous mixed oxygen difference were measured. Intravenous infusion of ilapidipine before, after recording ECG. Test in two steps medication, the first step, 30 minutes intravenous infusion of the product 0.1μg / kg per minute The second step, 30 minutes intravenous infusion